Immune dysfunction and epidermal barrier dysfunction are two key factors in the atopic dermatitis (AD) pathogenesis. “In my belief, the most promising approach is not improving the barrier function, but primarily using anti-inflammatory agents,” said Prof. Eric Simpson (Oregon Health & Science University, USA) .
At present, there are two important therapeutic gaps: “We need a more efficacious topical therapy than non-steroidals without significant burning or safety concern, and we would love to have pills in moderate-to-severe disease,” said Prof. Simpson. JAK inhibitors have the potential to fill these gaps. At present, there are two phase 2 trials with JAK inhibitors in AD.
A Japanese phase 2 study was performed with the topical JAK inhibitor delgocitinib in adult patients with moderate-to-severe AD . In this trial, the JAK inhibitor ointment, applied twice daily, led to a significant dose dependent change in the EASI (each dose P<0.0...
Please login to read the full text of the article.
If you have no account yet, please register now.